authors / representative study location,initial source,inclusion / exclusion,reason for exclusion,duplicate,study also found in search from representative samples (see column B),citations,,"Medrxiv, term 1","Medrxiv, term 2","PubMed, term 1","PubMed, term 2","Biorxiv, term 1","Biorxiv, term 2"
Doykov et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2022.02.14.22270845v1,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Bergeri et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.12.14.21267791v2,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
"Jouberton and Agincourt locations, later phases: Sun et al. ",Medrxiv (also search from representative samples),excluded,no median time between sampling nor start-month / end-month,Yes,Yes,https://www.medrxiv.org/content/10.1101/2022.02.11.22270854v1.full,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Gangelt location: Richter et al. ,Medrxiv (also search from representative samples),excluded,no non-serologic initial diagnosis,Yes,Yes,https://www.medrxiv.org/content/10.1101/2022.01.26.22269805v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Kantauskaite et al.,Medrxiv,excluded,"post-vaccine seroreversion, special population (kidney transplant recipients)",,,https://www.medrxiv.org/content/10.1101/2022.01.18.22269420v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Noordin et al.,Medrxiv,excluded,no sample size nor confidence intervals,,,https://www.medrxiv.org/content/10.1101/2022.01.16.22269388v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Kubale et al.,Medrxiv,excluded,special population (children),,,https://www.medrxiv.org/content/10.1101/2022.01.03.22268684v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Ghafari et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.10.04.21264540v2.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Tobolowsky et al.,Medrxiv,excluded,"post-vaccine seroreversion, special population (nursing home)",,,https://www.medrxiv.org/content/10.1101/2021.12.28.21268458v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Axfors + Ioannidis,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.07.08.21260210v2.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Yang + Shaman,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.12.19.21268073v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
McCance et al.,Medrxiv,included,"-  (excluded Menarini assay since sensitivity varied by lot, as occured with the Wondfo assay in other studies)",,,https://www.medrxiv.org/content/10.1101/2021.12.16.21267703v1.full-text  [ https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0266086 ],,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Menges et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (Luminex),,,https://www.medrxiv.org/content/10.1101/2021.12.15.21267776v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Levin et al. #2,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.09.29.21264325v3.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Germany SOEP location: Neuhauser et al.,Medrxiv (also search from representative samples),included,-,Yes,Yes,https://www.medrxiv.org/content/10.1101/2021.11.22.21266711v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Abela et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (ABCORA),,,https://www.medrxiv.org/content/10.1101/2021.04.21.21255410v2.full-text,https://www.nature.com/articles/s41467-021-27040-x,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Herrera-Esposito + de los Campos,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.07.29.21261282v2.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Otter et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.10.26.21265497v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
"France, national location: Warszawski et al.",Medrxiv (also search from representative samples),included,-,Yes,Yes,"https://www.medrxiv.org/content/10.1101/2021.10.25.21265456v1.full-text  ,  https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06973-0  [n-149]",,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Campbell + Gustafoson,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.05.12.21256975v4.full-text,https://www.cambridge.org/core/journals/epidemiology-and-infection/article/inferring-the-covid19-infection-fatality-rate-in-the-communitydwelling-population-a-simple-bayesian-evidence-synthesis-of-seroprevalence-study-data-and-imprecise-mortality-data/2BED7DA2109703060E07ABB6E79D96DD,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Beck et al.,Medrxiv,excluded,special population (hospitalized patients and healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.10.13.21264968v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
van den Hoogen et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (multiplex immunoassay),,,https://www.medrxiv.org/content/10.1101/2021.10.05.21264555v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Krutikov et al. #1,Medrxiv,excluded,special population (nursing home),Yes,,https://www.medrxiv.org/content/10.1101/2021.09.27.21264166v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,"PubMed: ""COVID-19 seroreversion""",,,
Stone et al. #1,Medrxiv,excluded,special population (hospitalized patients and blood donors),,,https://www.medrxiv.org/content/10.1101/2021.09.04.21262414v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Takahashi et al.,Medrxiv,excluded,no seroreversion data (quantification needed for figures 2 and supplementary figure 9),,,https://www.medrxiv.org/content/10.1101/2021.09.09.21263139v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Banaji et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.04.08.21255101v2.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Davis et al. #1,Medrxiv,excluded,special population (healthcare workers and postgraduate students),,,https://www.medrxiv.org/content/10.1101/2021.08.23.21261638v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Dick et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.08.17.21262188v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Van Gordon et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.08.18.21262248v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Dulovic et al.,Medrxiv,excluded,post-vaccine seroreversion,,,https://www.medrxiv.org/content/10.1101/2021.08.16.21262115v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Susswein et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.08.09.21261807v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
St. Petersburg location: Barchuk et al. #1,Medrxiv (also search from representative samples),excluded,assays not used individually,Yes,Yes,https://www.medrxiv.org/content/10.1101/2021.07.31.21261428v2.full-text,"https://eusp.org/news/k-seredine-avgusta-koronavirusom-perebolelo-menee-13-zhiteley-sankt-peterburga  ,  https://eusp.org/en/news/over-1-million-st-petersburg-residents-have-had-covid-19-since-the-onset-of-the-pandemic","Medrxiv: ""COVID-19 seroreversion""",,,,,
He et al. #1,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.03.25.21254281v4.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
He et al. #2,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.02.18.21251809v4.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Alleman et al.,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2020.07.17.20156034v4.full-text,https://www.sciencedirect.com/science/article/pii/S1755436521000542?via%3Dihub,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Nourbakhsh et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.07.19.21260773v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Renk et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (no seroreversion data for the commercial assays used),,,https://www.medrxiv.org/content/10.1101/2021.07.20.21260863v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Bouman et al.,Medrxiv (also search from representative samples),included,-,,Yes (Geneva [for Corona Immunitas]),https://www.medrxiv.org/content/10.1101/2021.07.19.21260410v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Ireland et al.,Medrxiv,excluded,special population (staff and students at schools),Yes,,https://www.medrxiv.org/content/10.1101/2021.07.14.21260502v2.full-text,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00430-2/fulltext,"Medrxiv: ""COVID-19 seroreversion""",,"PubMed: ""COVID-19 seroreversion""",,,
Ladhani et al.,Medrxiv,excluded,special population (staff and students at schools),,,https://www.medrxiv.org/content/10.1101/2021.07.14.21260496v1.full-text,https://www.journalofinfection.com/article/S0163-4453(21)00401-1/fulltext,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Hodgson et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.07.07.21260151v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Swadling et al.,Medrxiv,excluded,special population (healthcare workers),Yes,,https://www.medrxiv.org/content/10.1101/2021.06.26.21259239v1.full-text,https://www.nature.com/articles/s41586-021-04186-8,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Assefa et al.,Medrxiv,excluded,special population (pregnant women),,,https://www.medrxiv.org/content/10.1101/2021.06.17.21257323v1.full-text,https://bmjopen.bmj.com/content/11/11/e055834.long,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Brand et al.,Medrxiv,excluded,no seroreversion data,Yes,,https://www.medrxiv.org/content/10.1101/2021.06.17.21259100v1.full-text,https://www.science.org/doi/10.1126/science.abk0414,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Strengert et al.,Medrxiv,excluded,"post-vaccine seroreversion, special population (dialysis patients)",,,https://www.medrxiv.org/content/10.1101/2021.05.26.21257860v1.full-text,https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00317-0/fulltext,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Adiga et al.,Medrxiv,excluded,no seroreversion data,Yes,,https://www.medrxiv.org/content/10.1101/2021.05.26.21257836v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Allen et al.,Medrxiv,excluded,special population (healthcare workers),Yes,,https://www.medrxiv.org/content/10.1101/2021.05.25.21257772v1.full-text,https://journals.asm.org/doi/10.1128/Spectrum.00391-21,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Hartwig et al.,Medrxiv,excluded,Wondfo assay,,,https://www.medrxiv.org/content/10.1101/2021.05.21.21257634v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Castillo-Olivares et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.05.21.21257572v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Ortega et al.,Medrxiv,excluded,special population (healthcare workers),Yes,,https://www.medrxiv.org/content/10.1101/2021.02.22.21252150v2,https://www.nature.com/articles/s41467-021-24979-9,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Saluzzo et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.05.08.21256893v1.full-text,https://journals.asm.org/doi/10.1128/Spectrum.00250-21,"Medrxiv: ""COVID-19 seroreversion""",,,,,
"Dekalb + Fulton (COVIDVu, in Georgia) location: Chamberlain et al.",Medrxiv (also search from representative samples),excluded,subset of already included samples,Yes,Yes,https://www.medrxiv.org/content/10.1101/2021.05.06.21256407v1.full-text,https://doi.org/10.1093/infdis/jiab522,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Laing et al. #1,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (multiplex immunoassay and neutralization assay),Yes,,https://www.medrxiv.org/content/10.1101/2021.04.27.21256207v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Gonzalez et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (Luminex),,,https://www.medrxiv.org/content/10.1101/2021.04.28.21256122v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Sagara et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,Yes,,https://www.medrxiv.org/content/10.1101/2021.04.26.21256016v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Anderson et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.04.16.21255130v1.full-text,https://www.sciencedirect.com/science/article/pii/S1386653221001220?via%3Dihub,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Bottomley et al.,Medrxiv,excluded,no seroreversion data,Yes,,https://www.medrxiv.org/content/10.1101/2021.04.09.21254250v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Chandran et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.03.30.21254540v2.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Chaudhury et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.03.23.21253460v1.full-text,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0252628,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Pons-Salort et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.03.23.21254092v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Fernandez-Fuertes et al.,Medrxiv,excluded,special population (HIV patients),,,https://www.medrxiv.org/content/10.1101/2021.03.20.21253397v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Elyanow et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2021.03.19.21251426v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Perez-Saez et al.,Medrxiv (also search from representative samples),excluded,no non-serologic initial diagnosis,Yes,Yes (Geneva [for Corona Immunitas]),https://www.medrxiv.org/content/10.1101/2021.03.16.21253710v1.full-text,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00371-2/fulltext  [n-136],"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Chen et al. #1,Medrxiv,excluded,no seroreversion data,Yes (x2),,https://www.medrxiv.org/content/10.1101/2021.01.08.21249432v2.full-text,https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009436,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""","PubMed: ""COVID-19 seroreversion""",,,
Williamson et al.,Medrxiv,excluded,no seroreversion data,Yes,,https://www.medrxiv.org/content/10.1101/2021.03.11.21253226v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Spain national location: Pérez-Olmeda,Medrxiv (also search from representative samples),included,-,Yes,Yes,https://www.medrxiv.org/content/10.1101/2021.03.11.21253142v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
De Giorgi et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2021.03.08.21253093v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Becker et al.,Medrxiv,excluded,post-vaccine seroreversion,,,https://www.medrxiv.org/content/10.1101/2021.03.08.21252958v1.full-text,https://www.nature.com/articles/s41467-021-23473-6,"Medrxiv: ""COVID-19 seroreversion""",,,,,
García-Abellán et al.,Medrxiv,excluded,special population (hospitalized patients),Yes (x2),,https://www.medrxiv.org/content/10.1101/2021.03.08.21253124v1.full-text,https://link.springer.com/article/10.1007/s10875-021-01083-7,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""","PubMed: ""COVID-19 seroreversion""",,,
Meyer et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.03.04.21252939v1.full-text,https://academic.oup.com/aje/advance-article/doi/10.1093/aje/kwab273/6427250,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Peluso et al.,Medrxiv,included,-,Yes (x3),,https://www.medrxiv.org/content/10.1101/2021.03.03.21251639v1.full-text,https://www.science.org/doi/10.1126/sciadv.abh3409,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""","PubMed: ""COVID-19 seroreversion"" (twice)",,,
Menon et al.,Medrxiv,excluded,special population (healthcare workers),Yes,,https://www.medrxiv.org/content/10.1101/2021.03.02.21252362v1.full-text,https://bmjopen.bmj.com/content/11/10/e051045,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Fischer et al.,Medrxiv,excluded,special population (elderly/older cohort),,,https://www.medrxiv.org/content/10.1101/2021.02.23.21251891v1.full-text,https://www.mdpi.com/2075-1729/11/8/805,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Harris et al.,Medrxiv,excluded,special population (healthcare workers),"Yes (x3, including Fei et al.)",,https://www.medrxiv.org/content/10.1101/2020.10.21.20216689v2.full-text,https://www.journalofinfection.com/article/S0163-4453(21)00132-8/fulltext,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""","PubMed: ""COVID-19 seroreversion""",,,
Pei et al.,Medrxiv,excluded,no seroreversion data,Yes,,https://www.medrxiv.org/content/10.1101/2021.02.15.21251777v1.full-text,https://www.nature.com/articles/s41586-021-03914-4,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Chisolm et al.,Medrxiv,excluded,special population (pregnant women),,,https://www.medrxiv.org/content/10.1101/2021.02.08.21251367v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Gittelman et al.,Medrxiv (also search from representative samples),included,-,,Yes (Vo'),https://www.medrxiv.org/content/10.1101/2020.11.09.20228023v2.full,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
UK orthodox community location: Gaskell et al.,Medrxiv (also search from representative samples),excluded,no sample size nor confidence intervals,Yes,Yes,https://www.medrxiv.org/content/10.1101/2021.02.01.21250839v1.full,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Levorson et al.,Medrxiv,excluded,special population (children),,,https://www.medrxiv.org/content/10.1101/2021.01.28.21250466v1.full,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Herrington et al. (The COVID-19 Community Research Partnership Study Group),Medrxiv,excluded,no seroreversion data (absent numerical values for figure 2D),Yes,,https://www.medrxiv.org/content/10.1101/2021.01.27.21250615v1.full,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06517-6,"Medrxiv: ""COVID-19 seroreversion""",,"PubMed: ""COVID-19 seroreversion""",,,
Tea et al.,Medrxiv,included,-,Yes,,https://www.medrxiv.org/content/10.1101/2020.12.19.20248567v2.full-text,https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003656,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Bubar,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.09.08.20190629v3.full-text,https://www.science.org/doi/10.1126/science.abe6959,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Whitcombe et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (Luminex),Yes,,https://www.medrxiv.org/content/10.1101/2020.12.10.20246751v1.full-text,https://onlinelibrary.wiley.com/doi/10.1002/cti2.1261,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Pune location: Ghose et al.,Medrxiv (also search from representative samples),excluded,no seroreversion data,Yes,Yes,https://www.medrxiv.org/content/10.1101/2020.11.17.20228155v2.full-text  [n-84],,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Grandjean et al. #1,Medrxiv,excluded,special population (healthcare workers),Yes (x2),,https://www.medrxiv.org/content/10.1101/2020.11.20.20235697v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""","PubMed: ""COVID-19 seroreversion""",,,
Mieskolainen et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.11.19.20235036v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Lumley et al. #1,Medrxiv,excluded,special population (healthcare workers),Yes,,https://www.medrxiv.org/content/10.1101/2020.11.18.20234369v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Shioda et al.,Medrxiv,excluded,no seroreversion data,Yes (x3),,https://www.medrxiv.org/content/10.1101/2020.11.13.20231266v1.full-text,https://journals.lww.com/epidem/Fulltext/2021/07000/Estimating_the_Cumulative_Incidence_of_SARS_CoV_2.8.aspx,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""","PubMed: ""COVID-19 seroreversion"" (twice)",,,
Fisman et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.11.09.20223396v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Manisty et al.,Medrxiv,excluded,special population (healthcare workers),Yes,,https://www.medrxiv.org/content/10.1101/2020.11.04.20225920v2.full-text,https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00052-9/fulltext,"Medrxiv: ""COVID-19 seroreversion""",,"PubMed: ""COVID-19 seroreversion""",,,
Levin et al. #1,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.07.23.20160895v7.full-text,https://link.springer.com/article/10.1007/s10654-020-00698-1,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Mirzaie et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.10.22.20216317v1.full-text,https://brief.land/hepatmon/articles/111617.html,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Buss et al.,Medrxiv,excluded,no seroreversion data,Yes,,https://www.medrxiv.org/content/10.1101/2020.09.16.20194787v1.full-text,https://www.science.org/doi/10.1126/science.abe9728,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Snyder et al.,Medrxiv,excluded,assays not used individually,Yes,,https://www.medrxiv.org/content/10.1101/2020.07.31.20165647v3.full-text,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Rostami et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.08.31.20185017v1.full-text,https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30651-0/fulltext,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Moncunill et al.,Medrxiv,excluded,special population (healthcare workers),Yes,,https://www.medrxiv.org/content/10.1101/2020.08.23.20180125v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Leidner et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.08.16.20176107v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Cheng et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (peptide-protein hybrid microarray [PPHM] and unspecified CLIA),,,https://www.medrxiv.org/content/10.1101/2020.08.11.20172452v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Mariën et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.07.25.20161943v1.full-text,https://www.sciencedirect.com/science/article/pii/S0166093420302779?via%3Dihub,"Medrxiv: ""COVID-19 seroreversion""",,,,,
Iyer et al. #1,Medrxiv,excluded,special population (hospitalized patients),Yes,,https://www.medrxiv.org/content/10.1101/2020.07.18.20155374v1.full-text,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Rosado et al.,Medrxiv,excluded,no seroreversion data,Yes,,https://www.medrxiv.org/content/10.1101/2020.05.07.20093963v2.full,,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Alexander et al.,Medrxiv,excluded,no seroreversion data,Yes,,https://www.medrxiv.org/content/10.1101/2020.06.09.20125724v1.full,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247255,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Huang et al. #1,Medrxiv,excluded,no seroreversion data,Yes,,https://www.medrxiv.org/content/10.1101/2020.04.14.20065771v1.full,https://www.nature.com/articles/s41467-020-18450-4,"Medrxiv: ""COVID-19 seroreversion""","Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
The CONCOR-1 Study Group,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2021.06.29.21259427v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Bliden et al.,Medrxiv,excluded,post-vaccine,,,https://www.medrxiv.org/content/10.1101/2021.06.28.21259338v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Zhang et al.,Medrxiv,excluded,special population (first responders),,,https://www.medrxiv.org/content/10.1101/2021.06.27.21259432v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Davies et al. #1,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.06.21.21259254v2.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Gumel et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.12.11.20247916v4.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Adriaenssens et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.06.18.21259139v1.full-text,https://bmjopen.bmj.com/content/12/1/e054688,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Assefa et al.,Medrxiv,excluded,special population (women seeking antenatal care),,,https://www.medrxiv.org/content/10.1101/2021.06.17.21257323v1.full-text,https://bmjopen.bmj.com/content/11/11/e055834.long,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Chatterjee et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.06.15.21258935v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Psichogiou et al.,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2021.06.15.21258669v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Cohen et al. #1,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.04.19.21255739v2.full-text,https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00203-2,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Shan et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (saliva-based LFA),,,https://www.medrxiv.org/content/10.1101/2021.06.11.21258769v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Köppert et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.06.02.21258073v2.full-text,https://www.mdpi.com/2073-4409/10/8/1843,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Srivastava et al.,Medrxiv,excluded,special population (plasma donors),,,https://www.medrxiv.org/content/10.1101/2021.06.09.21258232v1.full,https://journals.asm.org/doi/10.1128/Spectrum.00830-21,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Miller et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.12.01.20241836v2.full,https://royalsocietypublishing.org/doi/10.1098/rsos.211021,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Pritchard et al.,Medrxiv,excluded,post-vaccine,,,https://www.medrxiv.org/content/10.1101/2021.04.22.21255913v2.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Soeorg et al.,Medrxiv,excluded,no seroreversion data (no seropositivity rate in figure 4a),,,https://www.medrxiv.org/content/10.1101/2021.06.06.21258406v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Lyski et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.05.28.21258025v1.full-text,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab585/6447629,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Scurr et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.06.02.21258218v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Caniels et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.05.26.21257441v1.full-text,https://www.science.org/doi/10.1126/sciadv.abj5365,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Waterlow et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.05.27.21257032v1.full-text,https://www.pnas.org/content/118/49/e2108395118,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
"Jouberton and Agincourt locations, early phases: Kleynhans et al.",Medrxiv (also search from representative samples),excluded,no non-serologic initial diagnosis,Yes,Yes,https://www.medrxiv.org/content/10.1101/2021.05.26.21257849v1.full-text,https://wwwnc.cdc.gov/eid/article/27/12/21-1465_article,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Yau et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.05.24.21257425v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ontañón et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.05.25.21257788v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Naaber et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.04.19.21255714v2.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Gutiérrez-Castrellón et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.05.20.21256954v1.full,https://www.tandfonline.com/doi/full/10.1080/19490976.2021.2018899,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Winklmeier et al.,Medrxiv,excluded,"no seroreversion data, special population (healthcare workers subset)",,,https://www.medrxiv.org/content/10.1101/2021.05.15.21257210v1.full-text,https://www.cell.com/iscience/fulltext/S2589-0042(21)01629-1,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Saeed et al. #1,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2021.05.13.21257177v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Gallais et al.,Medrxiv,excluded,"special population (healthcare workers), post-vaccine seroreversion",,,https://www.medrxiv.org/content/10.1101/2021.05.07.21256823v3.full-text,https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00354-6/fulltext,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Parry et al.,Medrxiv,excluded,post-vaccine,,,https://www.medrxiv.org/content/10.1101/2021.05.15.21257017v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Knabl et al.,Medrxiv,excluded,"post-vaccine, special population (elderly patients)",,,https://www.medrxiv.org/content/10.1101/2021.05.11.21256862v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Vaquero et al.,Medrxiv,excluded,post-vaccine,,,https://www.medrxiv.org/content/10.1101/2021.05.07.21256821v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
"Germany, 7 counties location (including Aachen, etc.): Gornyk et al.",Medrxiv (also search from representative samples),included,-,Yes,Yes,"https://www.medrxiv.org/content/10.1101/2021.05.04.21256597v2.full-text  ,  https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3834300  [n-26]",https://www.aerzteblatt.de/int/archive/article/221933  [n-173],,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Saeed et al. #2,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2021.05.11.21256992v1.full-text,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257743,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Mishra et al. #1,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.04.11.21255153v2.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Walti et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.05.10.21256634v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Byrum et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (multiSero),,,https://www.medrxiv.org/content/10.1101/2021.05.07.21249238v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Fulford et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (COVID-19 NAb-test),,,https://www.medrxiv.org/content/10.1101/2021.04.12.21255368v2.full-text,https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00523-5/fulltext,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Aliee et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.05.05.21256666v1.full-text,https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1009367,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Finch et al.,Medrxiv,excluded,special population (workplace sample),,,https://www.medrxiv.org/content/10.1101/2021.05.04.21256609v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Kennedy-Shaffer et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.05.03.21256556v1.full-text,https://journals.lww.com/epidem/Fulltext/2021/11000/Estimating_Vaccine_Efficacy_Against_Transmission.8.aspx,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Chen et al. #2,Medrxiv,excluded,no seroreversion data (assay-specific),,,https://www.medrxiv.org/content/10.1101/2021.05.03.21256506v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Zhou et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (Mike i1000),,,https://www.medrxiv.org/content/10.1101/2021.05.04.21256355v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Stone et al. #2,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2021.05.01.21255576v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ma et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.01.15.21249881v2.full-text,https://elifesciences.org/articles/66601,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Campos-Mata et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.04.29.21256002v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Toubat et al.,Medrxiv,excluded,special population (firefighters),,,https://www.medrxiv.org/content/10.1101/2021.04.20.21255829v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Wei et al.,Medrxiv,excluded,post-vaccine seroreversion,,,https://www.medrxiv.org/content/10.1101/2021.04.22.21255911v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Trento (5 municipalities) location: Manica et al.,Medrxiv,excluded,no seroreversion data,Yes,Yes,https://www.medrxiv.org/content/10.1101/2021.04.14.21255502v1.full,https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab556/6301134,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Choudhary et al. #1,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.03.02.21252750v2.full,https://academic.oup.com/cid/article/74/2/237/6255966?login=false,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Scherlinger et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.04.08.21255167v1.full-text,https://link.springer.com/article/10.1007/s40121-021-00484-w,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Rane et al.,Medrxiv,excluded,no seroreversion data (assay-specific),,,https://www.medrxiv.org/content/10.1101/2021.04.06.21255009v3.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Glampson et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.04.08.21254580v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Verissimo et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.04.07.21255024v1.full-text,https://www.cambridge.org/core/journals/epidemiology-and-infection/article/improved-diagnosis-of-sarscov2-by-using-nucleoprotein-and-spike-protein-fragment-2-in-quantitative-dual-elisa-tests/728A54ABFEBAAA4605F3E37A48E22FA5,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Dopico et al.,Medrxiv,excluded,"special population (blood donors, pregnant women)",,,https://www.medrxiv.org/content/10.1101/2020.12.24.20248821v2.full-text,https://onlinelibrary.wiley.com/doi/10.1111/joim.13304,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Davis et al. #2,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.12.24.20248802v3.full-text,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00299-6/fulltext,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Loyal et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.04.01.21252379v1.full-text,https://www.science.org/doi/10.1126/science.abh1823,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Klein et al.,Medrxiv,excluded,special population (transplant recipient),,,https://www.medrxiv.org/content/10.1101/2021.03.24.21253992v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Di Germanio et al.,Medrxiv,excluded,special population (blood donors),Yes,,https://www.medrxiv.org/content/10.1101/2021.03.24.21254260v1.full-text,https://onlinelibrary.wiley.com/doi/10.1111/trf.16555,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,"PubMed: ""COVID-19 longitudinal, antibody waning""",,
Mohanraj et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.03.19.21253518v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Padmanabhan et al.,Medrxiv,excluded,"no seroreversion data, post-vaccine",,,https://www.medrxiv.org/content/10.1101/2021.03.16.21253742v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Val Gardena + associated regions: Melotti et al.,Medrxiv,excluded,no seroreversion data,Yes,Yes,https://www.medrxiv.org/content/10.1101/2021.03.19.21253883v1.full-text,https://www.cambridge.org/core/journals/epidemiology-and-infection/article/prevalence-and-determinants-of-serum-antibodies-to-sarscov2-in-the-general-population-of-the-gardena-valley/43FAD8F3CD0983D4427D3A10D1AC8063,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Eberhardt et al.,Medrxiv,included,-,Yes (Fei et al.),,https://www.medrxiv.org/content/10.1101/2021.03.10.21253288v1.full,https://www.mdpi.com/2076-2607/9/4/733,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Monin-Aldama et al.,Medrxiv,excluded,post-vaccine,,,https://www.medrxiv.org/content/10.1101/2021.03.17.21253131v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Jagtap et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.10.13.20182949v2.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Alkharaan et al.,Medrxiv,included,-,,,https://www.medrxiv.org/content/10.1101/2021.03.13.21253492v1.full,https://academic.oup.com/jid/article/224/3/407/6274637,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Etyang et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.03.12.21253493v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Huynh et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.09.11.20192690v2.full,https://www.mdpi.com/1999-4915/13/4/697/htm,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Jung et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.03.04.21252658v2.full-text,https://www.nature.com/articles/s41467-021-24377-1,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Krutikov et al. #2,Medrxiv,excluded,special population (nursing home residents and healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.03.08.21253110v1.full-text,https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00093-3/fulltext,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Anand et al. #1,Medrxiv,excluded,special population (dialysis patients),,,https://www.medrxiv.org/content/10.1101/2021.03.07.21252786v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Deng et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Barrio Padre Mugica location: Pagotto et al.,Medrxiv (also search from representative samples),excluded,no non-serologic initial diagnosis,Yes,Yes,https://www.medrxiv.org/content/10.1101/2021.03.05.21253010v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Pelleau et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.03.04.21252532v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Goel et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.03.03.21252872v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Davies et al. #2,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.12.24.20248822v3.full-text,https://www.science.org/doi/10.1126/science.abg3055,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Faria et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.02.26.21252554v1.full-text,https://www.science.org/doi/10.1126/science.abh2644,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Qiu et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.03.01.21252411v1.full-text,https://jlb.onlinelibrary.wiley.com/doi/10.1002/JLB.5MA0721-825R,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Truong et al.,Medrxiv,excluded,special population (young leukemia patients),,,https://www.medrxiv.org/content/10.1101/2021.02.27.21252099v1.full-text,https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00148-1/fulltext,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Gonzalez-Parra et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.02.24.21252406v1.full-text,https://www.mdpi.com/2297-8747/26/2/25/htm,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Shields et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.02.24.21252368v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Dehgani-Mobaraki et al. #1,Medrxiv,excluded,special population (largely healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.02.22.21252225v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Martínez-Rodríguez et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.02.19.21252095v1.full-text,https://www.mdpi.com/2673-3986/2/2/12/htm,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Feng et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.02.17.21251867v2.full-text,https://pubs.acs.org/doi/10.1021/acsestwater.1c00160,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Dispinseri et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (luciferase immune precipitation assay),,,https://www.medrxiv.org/content/10.1101/2021.02.17.21251929v1.full-text,https://www.nature.com/articles/s41467-021-22958-8,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Narasimhan et al.,Medrxiv,excluded,special population (hospitalized inpatients),,,https://www.medrxiv.org/content/10.1101/2021.02.17.21251940v1.full-text,https://journals.asm.org/doi/10.1128/JCM.00388-21,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Martin et al.,Medrxiv,excluded,"post-vaccine, special population (healthcare workers)",,,https://www.medrxiv.org/content/10.1101/2021.02.11.21251548v3.full,https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003823,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Malosh et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.02.16.21251827v1.full,https://academic.oup.com/cid/article/73/7/1248/6265275?login=false,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Hay et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.10.08.20204222v2.full,https://www.science.org/doi/10.1126/science.abh0635,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Laing et al. #2,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.02.10.21251518v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Adetifa et al. ,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2021.02.09.21251404v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Luo et al. #1,Medrxiv,excluded,no seroreversion data (quantification needed for commercial antibody),,,https://www.medrxiv.org/content/10.1101/2021.01.19.21250137v3.full,https://journals.asm.org/doi/10.1128/JCM.00193-21,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Davis et al. #3,Medrxiv,excluded,special population (graduate students and staff),,,https://www.medrxiv.org/content/10.1101/2020.12.07.20245183v2.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Guimarães,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.02.06.21251251v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Follmann + Fay,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.02.04.21251133v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Tang et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.02.03.21250928v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Crellen et al.,Medrxiv,excluded,no seroreversion data,Yes,,https://www.medrxiv.org/content/10.1101/2020.07.24.20157982v2.full,https://royalsocietypublishing.org/doi/10.1098/rstb.2020.0274,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,"PubMed: ""COVID-19 longitudinal, antibody waning""",,
Markmann et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2021.02.01.21250493v1.full,https://journals.asm.org/doi/10.1128/mSphere.00275-21,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Leister et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2021.02.01.21250898v1.full,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06586-7,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Longueira et al.,Medrxiv,included,-,,,https://www.medrxiv.org/content/10.1101/2021.01.31.21250167v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Wang et al. #1,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.12.10.20247205v5.full-text,https://www.nature.com/articles/s41586-021-03631-y,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Lewis et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.01.25.21250189v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Tan et al. #1,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2021.01.24.21250074v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Mallon et al.,Medrxiv,included,-,,,https://www.medrxiv.org/content/10.1101/2021.01.24.20248381v1.full,https://academic.oup.com/ofid/article/8/8/ofab122/6188617,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Clarke et al.,Medrxiv,excluded,special population (dialysis patients),,,https://www.medrxiv.org/content/10.1101/2021.01.22.21249865v1.full-text,https://www.kidney-international.org/article/S0085-2538(21)00295-7/fulltext,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Nicholson et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.01.21.21250249v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Lewnard et al. #1,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.01.21.21250258v1.full-text,https://journals.lww.com/epidem/Abstract/2021/07000/Theoretical_Framework_for_Retrospective_Studies_of.7.aspx,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Zuñiga et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.01.16.21249956v1.full,https://journals.sagepub.com/doi/10.1177/17534666211028077,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Cleary et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.05.01.20086801v3.full-text,https://www.science.org/doi/10.1126/scitranslmed.abf1568,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Stephenson et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.01.13.21249725v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Moncla et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.10.19.20215442v2.full-text,https://elifesciences.org/articles/66448,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Dalai et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.01.06.21249345v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Steenhius et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2021.01.06.20249035v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Perkins et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.01.06.21249311v1.full-text,https://www.science.org/doi/10.1126/sciadv.abg5033,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Hachim et al. #1,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (luciferase immune precipitation assay),,,https://www.medrxiv.org/content/10.1101/2021.01.03.21249180v2.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Robertson et al,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.04.28.20080630v2.full-text,https://bmjopen.bmj.com/content/11/9/e048778.long,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Trombetta et al.,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2021.01.02.20248998v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Friston et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2021.01.03.20248972v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Lewnard et al. #2,Medrxiv,excluded,special population (farmworkers),,,https://www.medrxiv.org/content/10.1101/2020.12.27.20248894v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Kemp et al.,Medrxiv,excluded,no seroreversion data (quantification of number of seropositive samples),,,https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v3.full,https://www.nature.com/articles/s41586-021-03291-y,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Yuen et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.09.15.20192765v4.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Wagner et al.,Medrxiv,excluded,special population (employees),,,https://www.medrxiv.org/content/10.1101/2020.12.22.20248604v1.full,https://www.nature.com/articles/s43856-021-00012-4,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Harvey et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.12.18.20248336v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Wallace et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.12.15.20247981v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Huen et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.11.08.20227975v3.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Follmann et al.,Medrxiv,excluded,post-vaccine,,,https://www.medrxiv.org/content/10.1101/2020.12.14.20248137v1.full,https://www.acpjournals.org/doi/10.7326/M20-8149,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Lee et al. #1,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.12.13.20248143v1.full,https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00129-4,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Taubel et al.,Medrxiv,excluded,special population (largely healthcare workers and visitors),,,https://www.medrxiv.org/content/10.1101/2020.12.08.20245894v2.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Lee et al. #2,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2020.12.02.20242750v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Stoddard et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.11.29.20240440v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Dehgani-Mobaraki et al. #2,Medrxiv,excluded,special population (largely healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.11.21.20236117v2.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ragonnet et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.08.25.20182162v2.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Chiang et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.11.12.20230656v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Wendel et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2020.11.12.20230391v1.full-text,https://onlinelibrary.wiley.com/doi/10.1111/trf.16323,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Grzelak et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.11.12.20230466v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Makatsa et al.,Medrxiv,excluded,no seroreversion data (some samples collected before time of seroconversion),,,https://www.medrxiv.org/content/10.1101/2020.08.04.20167940v2.full-text,https://www.frontiersin.org/articles/10.3389/fpls.2021.589940/full,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Keshavarz et al.,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2020.11.09.20228411v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Selhorst et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.11.05.20225052v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Jin et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2020.11.06.20220087v1.full-text,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0250319,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Sieling et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.11.04.20225417v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Lumley et al. #2,Medrxiv,excluded,special population (healthcare workers),Yes,,https://www.medrxiv.org/content/10.1101/2020.11.02.20224824v1.full,https://academic.oup.com/cid/article/73/3/e699/6064824,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,"PubMed: ""COVID-19 longitudinal, antibody waning""",,
St. Petersburg location: Barchuk et al. #2,Medrxiv (also search from representative samples),excluded,no seroreversion data,Yes,Yes,https://www.medrxiv.org/content/10.1101/2020.11.02.20221309v1.full,https://www.nature.com/articles/s41598-021-92206-y,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Murrell et al.,Medrxiv,excluded,special population (healthcare workers and hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2020.10.29.20219931v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ogega et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.10.28.20220996v1.full,https://www.jci.org/articles/view/145516,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Magalhães et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.10.25.20218735v2.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Garritsen et al.,Medrxiv,included,-,,,https://www.medrxiv.org/content/10.1101/2020.10.07.20187641v2.full,https://www.tandfonline.com/doi/full/10.1080/23744235.2021.1893378,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
England location (REACT-2): Ward et al.,Medrxiv (also search from representative samples),included,-,Yes,Yes,"https://www.medrxiv.org/content/10.1101/2020.10.26.20219725v1.full-text  ,  https://www.nature.com/articles/s41467-021-21237-w  [n-14]","https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00075-2/fulltext  [n-102]  ,  https://www.medrxiv.org/content/10.1101/2021.07.21.21260926v1.supplementary-material  [n-15]",,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ojeda et al.,Medrxiv,included,-,Yes,,https://www.medrxiv.org/content/10.1101/2020.10.21.20216960v1.full-text,https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009161,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,"PubMed: ""COVID-19 longitudinal, antibody waning""",,
Boonyaratanakornkit et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2020.10.06.20207472v2.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Le Vu et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.10.20.20213116v1.full-text,https://www.nature.com/articles/s41467-021-23233-6,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Garcia-Beltran et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.10.15.20213512v1.full-text,https://www.cell.com/cell/fulltext/S0092-8674(20)31685-8,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Laing et al. #3,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (multiplex microsphere-based immunoassay),,,https://www.medrxiv.org/content/10.1101/2020.10.14.20207050v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Prowse et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.09.25.20201939v3.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Reynolds et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.10.13.20211763v1.full-text,https://www.science.org/doi/10.1126/sciimmunol.abf3698,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Fotis et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2020.09.09.20191122v2.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Mortgat et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.10.03.20204545v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Thompson et al. #1,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.09.10.20186064v2.full,https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00177-7,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Abo-Leyah et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.10.02.20205641v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
O'Nions et al.,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2020.09.29.20202846v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Fozouni et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.09.28.20201947v1.full,https://www.cell.com/cell/fulltext/S0092-8674(20)31623-8,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ogbe et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.09.28.20202929v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Abu Raddad et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.08.24.20179457v2.full,https://academic.oup.com/cid/article/73/7/e1830/6033728,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Goldman et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.09.22.20192443v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Hashem et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.09.21.20198309v1.full-text,https://www.mdpi.com/1999-4915/12/12/1390,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Gregorova et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.09.17.20190033v1.full-text,https://elifesciences.org/articles/63430,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Vassallo et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2020.09.17.20195131v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Kainulainen et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.09.16.20195446v1.full,https://www.nature.com/articles/s41598-021-91300-5,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Newell et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.09.04.20187724v2.full,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244855,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Rigatti et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.09.09.20191296v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Bortz III et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.09.10.20192187v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Wheatley et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.09.09.20191205v2.full,https://www.nature.com/articles/s41467-021-21444-5,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Luo et al. #2,Medrxiv,excluded,no seroreversion data (lack quantified number of seropositives),,,https://www.medrxiv.org/content/10.1101/2020.07.30.20165522v4.full-text,https://academic.oup.com/cid/article/73/9/e3095/5905578,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Lavine et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.09.03.20187856v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ojal et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2020.09.02.20186817v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Annen et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2020.09.01.20185942v1.full-text,https://onlinelibrary.wiley.com/doi/10.1111/trf.16261,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Meyer et al.,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2020.08.31.20184895v1.full-text,https://onlinelibrary.wiley.com/doi/10.1111/trf.16321,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Legros et al.,Medrxiv,excluded,"no seroreversion data (lack quantified number of seropositives), special population (largely hospitalized patients)",,,https://www.medrxiv.org/content/10.1101/2020.08.27.20182493v1.full-text,https://www.nature.com/articles/s41423-020-00588-2,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Post et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.08.25.20178806v1.full,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0244126,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Shrotri et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.08.24.20180679v1.full,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0245532,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Isho et al. (via Canada [Ab-C] location),Medrxiv (also search from representative samples),included,-,Yes,Yes,https://www.medrxiv.org/content/10.1101/2020.08.01.20166553v2.full,https://www.science.org/doi/10.1126/sciimmunol.abe5511,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Oguntuyo et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.08.13.20157222v2.full,https://journals.asm.org/doi/10.1128/mBio.02492-20,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Tighe et al.,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2020.08.22.20176834v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Rathe et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.08.18.20177196v1.full-text,https://academic.oup.com/jid/article/223/7/1120/6047577,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ripperger et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.08.14.20174490v1.full-text,https://www.cell.com/immunity/fulltext/S1074-7613(20)30445-3,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Rodda et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.08.11.20171843v2.full,https://www.cell.com/cell/fulltext/S0092-8674(20)31565-8,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Emmenegger et al.,Medrxiv,excluded,special population (hospitalized patients and blood donors),,,https://www.medrxiv.org/content/10.1101/2020.05.31.20118554v4.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Crawford et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.08.06.20169367v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Muecksch et al.,Medrxiv,included,-,Yes (Fei et al.),,https://www.medrxiv.org/content/10.1101/2020.08.05.20169128v1.full-text,https://academic.oup.com/jid/article/223/3/389/5952470,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Butler et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.08.05.20168971v1.full,https://www.frontiersin.org/articles/10.3389/fimmu.2020.618685/full,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Cohen et al. #2,Medrxiv,excluded,special population (dialysis patients),,,https://www.medrxiv.org/content/10.1101/2020.08.03.20163642v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Zeng et al.,Medrxiv,excluded,"special population (hospitalized patients, heatlhcare workers, and blood donors)",,,https://www.medrxiv.org/content/10.1101/2020.08.02.20166819v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ke et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.07.31.20166298v1.full,https://www.sciencedirect.com/science/article/pii/S0022519321000436,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Brehm et al.,Medrxiv,excluded,special population (heatlhcare workers),,,https://www.medrxiv.org/content/10.1101/2020.07.31.20165936v2.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ferretti et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.07.24.20161653v2.full,https://www.cell.com/immunity/fulltext/S1074-7613(20)30447-7,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Thompson et al. #2,Medrxiv,excluded,special population (blood donors),,,https://www.medrxiv.org/content/10.1101/2020.04.13.20060467v2.full,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.42.2000685,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Lennon et al.,Medrxiv,excluded,special population (nursing home residents and healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.07.20.20157792v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Grandjean et al. #2,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.07.16.20155663v2.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Unterman et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.07.16.20153437v1.full,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Wajnberg et al.,Medrxiv,excluded,no seroreversion data (quantification of number of seropositive samples),,,https://www.medrxiv.org/content/10.1101/2020.07.14.20151126v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ioannidis,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.05.13.20101253v3.full-text,https://www.who.int/bulletin/volumes/99/1/20-265892.pdf,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Seow et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.07.09.20148429v1.full-text,https://www.nature.com/articles/s41564-020-00813-8,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Coste et al.,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2020.07.09.20149864v1.full-text,https://www.sciencedirect.com/science/article/pii/S1386653220304327,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Yang et al.,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2020.07.01.20144030v1.full-text,https://academic.oup.com/jmcb/article/13/3/197/6159619,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Eyre et al.,Medrxiv,excluded,special population (nursing home residents),,,https://www.medrxiv.org/content/10.1101/2020.06.24.20135038v2.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Micochova et al.,Medrxiv,excluded,special population (hospitalized patients),,,https://www.medrxiv.org/content/10.1101/2020.06.16.20133157v3.full-text,https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(20)30125-7,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Houlihan et al.,Medrxiv,excluded,special population (healthcare workers),,,https://www.medrxiv.org/content/10.1101/2020.06.08.20120584v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Lynch et al.,Medrxiv,excluded,"non-commercial in-house assay + not used in seroprevalence study, special population (largely hospitalized patients)",,,https://www.medrxiv.org/content/10.1101/2020.06.03.20121525v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Ng + Goldgof et al.,Medrxiv,excluded,special population (hospitalized patients and blood donors),,,https://www.medrxiv.org/content/10.1101/2020.05.19.20107482v2.full-text,https://www.nature.com/articles/s41467-020-18468-8,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Brett et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.04.29.20082065v1.full-text,https://www.pnas.org/content/117/41/25897,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Galanti et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.04.27.20082032v1.full-text,https://academic.oup.com/jid/article/223/3/409/5868459,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Hachim et al. #2,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (luciferase immune precipitation assay),,,https://www.medrxiv.org/content/10.1101/2020.04.30.20085670v1.full-text,https://www.nature.com/articles/s41590-020-0773-7,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Burbelo et al.,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (luciferase immune precipitation assay),,,https://www.medrxiv.org/content/10.1101/2020.04.20.20071423v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Wang et al. #2,Medrxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.medrxiv.org/content/10.1101/2020.04.15.20065623v3.full-text,https://academic.oup.com/cid/article/71/10/2688/5851474,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Braun et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.04.17.20061440v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Amanat et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.03.17.20037713v2.full-text,https://www.nature.com/articles/s41591-020-0913-5,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Wölfel et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.03.05.20030502v1.full-text,,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Kissler et al.,Medrxiv,excluded,no seroreversion data,,,https://www.medrxiv.org/content/10.1101/2020.03.04.20031112v1.full-text,https://www.science.org/doi/10.1126/science.abb5793,,"Medrxiv: ""COVID-19 longitudinal, antibody waning""",,,,
Schönborn et al.,PubMed,excluded,no seroreversion data,,,https://pubmed.ncbi.nlm.nih.gov/35113987/,https://ashpublications.org/blood/article/doi/10.1182/blood.2021014214/483827/Most-Anti-PF4-Antibodies-in-Vaccine-induced-Immune,,,"PubMed: ""COVID-19 seroreversion""",,,
Ogundipe,PubMed,excluded,no seroreversion data,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791411/,,,,"PubMed: ""COVID-19 seroreversion""",,,
Weigert et al.,PubMed,excluded,"post-vaccine, special population (dialysis patients)",,,https://pubmed.ncbi.nlm.nih.gov/35004771/,https://www.frontiersin.org/articles/10.3389/fmed.2021.796676/full,,,"PubMed: ""COVID-19 seroreversion""",,,
Mishra et al. #2,PubMed,excluded,"post-vaccine, special population (healthcare workers)",,,https://pubmed.ncbi.nlm.nih.gov/34976499/,https://www.cureus.com/articles/76494-waning-of-anti-spike-antibodies-in-azd1222-chadox1-vaccinated-healthcare-providers-a-prospective-longitudinal-study,,,"PubMed: ""COVID-19 seroreversion""",,,
Barcellini et al.,PubMed,excluded,special population (students at schools),,,https://pubmed.ncbi.nlm.nih.gov/34473776/,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0257046,,,"PubMed: ""COVID-19 seroreversion""",,,
Portilho et al.,PubMed,excluded,special population (largely hospitalized patients and/or healthcare workers),,,https://pubmed.ncbi.nlm.nih.gov/34428312/,https://onlinelibrary.wiley.com/doi/10.1002/jmv.27290,,,"PubMed: ""COVID-19 seroreversion""",,,
Bond et al.,PubMed,included,-,,,https://pubmed.ncbi.nlm.nih.gov/34412859/,https://www.pathologyjournal.rcpa.edu.au/article/S0031-3025(21)00417-7/fulltext,,,"PubMed: ""COVID-19 seroreversion""",,,
Peghin et al.,PubMed,excluded,no seroreversion data (quantification needed for figure 2 [YHLO iFlash SARS CoV-2]),,,https://pubmed.ncbi.nlm.nih.gov/34379530/,https://journals.asm.org/doi/full/10.1128/JCM.01138-21,,,"PubMed: ""COVID-19 seroreversion""",,,
Masiá et al.,PubMed,excluded,special population (hospitalized patients),,,https://pubmed.ncbi.nlm.nih.gov/34303083/,https://www.sciencedirect.com/science/article/pii/S0896841121001116?via%3Dihub,,,"PubMed: ""COVID-19 seroreversion""",,,
Song et al.,PubMed,excluded,special population (pregnant women),,,https://pubmed.ncbi.nlm.nih.gov/34234001/,https://bmjopen.bmj.com/content/11/7/e053036.long,,,"PubMed: ""COVID-19 seroreversion""",,,
Hamer et al.,PubMed,excluded,no seroreversion data (non-human animals),,,https://pubmed.ncbi.nlm.nih.gov/34069453/,https://www.mdpi.com/1999-4915/13/5/938/htm,,,"PubMed: ""COVID-19 seroreversion""",,,
Papasavas et al.,PubMed,excluded,special population (healthcare workers),,,https://pubmed.ncbi.nlm.nih.gov/33930487/,https://www.journalofhospitalinfection.com/article/S0195-6701(21)00174-2/fulltext,,,"PubMed: ""COVID-19 seroreversion""",,,
Poland,PubMed,excluded,no seroreversion data,,,https://pubmed.ncbi.nlm.nih.gov/33730754/,https://academic.oup.com/cid/article/73/12/2163/6175316,,,"PubMed: ""COVID-19 seroreversion""",,,
Soriano et al.,PubMed,excluded,no non-serologic initial diagnosis,,,https://pubmed.ncbi.nlm.nih.gov/33684560/,https://www.ijidonline.com/article/S1201-9712(21)00201-0/fulltext  [n-241],,,"PubMed: ""COVID-19 seroreversion""",,,
Self et al.,PubMed,excluded,special population (healthcare workers),,,https://pubmed.ncbi.nlm.nih.gov/33237893/,https://www.cdc.gov/mmwr/volumes/69/wr/mm6947a2.htm,,,"PubMed: ""COVID-19 seroreversion""",,,
Niess et al.,PubMed,excluded,special population (transplant recipient),,,https://pubmed.ncbi.nlm.nih.gov/33047475/,https://onlinelibrary.wiley.com/doi/10.1111/ajt.16349,,,"PubMed: ""COVID-19 seroreversion""",,,
Iyer et al. #2,PubMed,excluded,special population (largely hospitalized patients),,,https://pubmed.ncbi.nlm.nih.gov/33033172/,https://www.science.org/doi/10.1126/sciimmunol.abe0367,,,"PubMed: ""COVID-19 seroreversion""",,,
Rodríguez-Tajes et al.,PubMed,excluded,special population (hospitalized patients),,,https://pubmed.ncbi.nlm.nih.gov/32969557/,https://onlinelibrary.wiley.com/doi/10.1111/jvh.13410,,,"PubMed: ""COVID-19 seroreversion""",,,
Chia et al.,PubMed,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://pubmed.ncbi.nlm.nih.gov/33778792/,https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00025-2/fulltext,,,,"PubMed: ""COVID-19 longitudinal, antibody waning""",,
Sakharkar et al.,PubMed,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://pubmed.ncbi.nlm.nih.gov/33622975/,https://www.science.org/doi/10.1126/sciimmunol.abg6916,,,,"PubMed: ""COVID-19 longitudinal, antibody waning""",,
Crooke et al.,PubMed,excluded,no seroreversion data,,,https://pubmed.ncbi.nlm.nih.gov/33190948/,https://www.sciencedirect.com/science/article/pii/S0264410X20313967,,,,"PubMed: ""COVID-19 longitudinal, antibody waning""",,
Perreault et al.,PubMed,excluded,special population (plasma donors),Yes,,https://pubmed.ncbi.nlm.nih.gov/33001206/,https://ashpublications.org/blood/article/136/22/2588/463996/Waning-of-SARS-CoV-2-RBD-antibodies-in,,,,"PubMed: ""COVID-19 longitudinal, antibody waning""",,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Seadawy et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.11.07.367649v1.full,https://biomedres.us/fulltexts/BJSTR.MS.ID.005552.php,,,,"Biorxiv: ""COVID-19 seroreversion""",,
Zeiss et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.05.11.443477v1.full,,,,,"Biorxiv: ""COVID-19 seroreversion""",,
McLeod et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.06.01.446592v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Talla et al.,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.biorxiv.org/content/10.1101/2021.05.26.442666v3.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Tan et al. #2,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.06.29.450293v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Narowski et al.,Biorxiv,excluded,special population (healthcare workers),,,https://www.biorxiv.org/content/10.1101/2021.06.19.449100v1.full,https://www.cell.com/cell-reports/fulltext/S2211-1247(22)00052-3,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Wuertz et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.06.16.448525v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Jeffery-Smith et al.,Biorxiv,excluded,special population (nursing home residents and healthcare workers),,,https://www.biorxiv.org/content/10.1101/2021.05.30.446322v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Forgacs et al.,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.biorxiv.org/content/10.1101/2021.05.29.445137v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Assis et al.,Biorxiv,excluded,special population (healthcare workers),,,https://www.biorxiv.org/content/10.1101/2021.04.15.440089v4.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Pegu et al.,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Sheward et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.04.03.438330v2.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Gallagher et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
King et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.04.09.439166v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Garrido et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.04.05.438479v1.full,https://www.science.org/doi/10.1126/sciimmunol.abj3684,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Wu et al.,Biorxiv,excluded,no non-serologic initial diagnosis,,,https://www.biorxiv.org/content/10.1101/2021.03.26.437123v1.full,https://www.frontiersin.org/articles/10.3389/fimmu.2021.722027/full  [n-242],,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Sandberg et al.,Biorxiv,excluded,special population (hospitalized patients),,,https://www.biorxiv.org/content/10.1101/2021.03.17.435581v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Ketas et al.,Biorxiv,excluded,post-vaccine,,,https://www.biorxiv.org/content/10.1101/2021.03.11.434841v1.full,https://www.paijournal.com/index.php/paijournal/article/view/441,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Tong et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.03.10.434840v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Alrubayyi et al.,Biorxiv,excluded,special population (HIV patients),,,https://www.biorxiv.org/content/10.1101/2021.02.15.431215v1.full,https://www.nature.com/articles/s41467-021-26137-7,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Lim et al.,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.biorxiv.org/content/10.1101/2021.02.10.430668v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Zhang et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.01.30.428920v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Collora et al.,Biorxiv,excluded,special population (HIV patients),,,https://www.biorxiv.org/content/10.1101/2021.01.27.428491v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Crooks et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2021.01.25.428184v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Vanshylla et al.,Biorxiv,included,-,,,https://www.biorxiv.org/content/10.1101/2021.01.26.428207v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Anand et al. #3,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.biorxiv.org/content/10.1101/2021.01.25.428097v1.full,https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00118-X,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Quadeer et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.08.26.267724v2.full,https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00155-5,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Castro et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.12.26.424449v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Ferrantelli et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.12.18.423420v1.full,https://www.mdpi.com/2076-393X/9/3/240/htm,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Dan et al.,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.biorxiv.org/content/10.1101/2020.11.15.383323v2.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Lehmann et al.,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.biorxiv.org/content/10.1101/2020.11.29.402677v1.full,https://www.frontiersin.org/articles/10.3389/fimmu.2021.635942/full,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Pradenas et al.,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study,,,https://www.biorxiv.org/content/10.1101/2020.11.22.389056v2.full,https://www.cell.com/med/fulltext/S2666-6340(21)00035-0,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
 Li et al. #2,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.11.15.383463v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Andreoletti et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.10.30.362715v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Ferreras et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.10.23.352294v1.full,https://www.frontiersin.org/articles/10.3389/fcell.2021.620730/full,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Anand et al. #4,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.10.20.346783v1.full,https://onlinelibrary.wiley.com/doi/10.1111/trf.16318,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Tan et al. #3,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (Luminex),,,https://www.biorxiv.org/content/10.1101/2020.10.15.341958v1.full,https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00041-3,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Cross et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.10.14.340091v1.full,https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00151-0,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Gasser et al.,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (Luminex),,,https://www.biorxiv.org/content/10.1101/2020.10.09.333278v1.full,https://www.cell.com/cell-reports/fulltext/S2211-1247(21)00104-2,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Pan et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.10.01.322958v1.full,https://www.cell.com/immunity/fulltext/S1074-7613(21)00185-0,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Khan et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.06.21.163394v2.full,https://insight.jci.org/articles/view/144499,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Takagi + Matsui,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.09.18.304493v1.full,https://journals.asm.org/doi/full/10.1128/JVI.01837-20,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Tan et al. #4,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.09.01.278630v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Gontu et al.,Biorxiv,excluded,special population (plasma donors),,,https://www.biorxiv.org/content/10.1101/2020.08.21.261909v1.full,https://www.nature.com/articles/s42003-021-01813-y,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Noval et al.,Biorxiv,excluded,"special population (healthcare workers),",,,https://www.biorxiv.org/content/10.1101/2020.08.15.252353v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Schulien et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.08.13.249433v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Prévost et al.,Biorxiv,excluded,non-commercial in-house assay + not used in seroprevalence study (Luminex),,,https://www.biorxiv.org/content/10.1101/2020.06.08.140244v3.full,https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(20)30168-3,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Weisblum et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full,https://elifesciences.org/articles/61312,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Christian + Murrell,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.07.14.202150v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Sekine et al.,Biorxiv,excluded,special population (largely blood donors and hospitalized individuals),,,https://www.biorxiv.org/content/10.1101/2020.06.29.174888v1.full,https://www.cell.com/cell/fulltext/S0092-8674(20)31008-4,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Lieberman et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.06.22.165225v1.full,https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3000849,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Goyal et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.06.21.163550v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Le Sage et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.06.15.103747v1.full,https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009273,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Woolsey et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.05.17.100289v1.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Wec et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.05.15.096511v2.full,,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Korber et al.,Biorxiv,excluded,no seroreversion data,,,https://www.biorxiv.org/content/10.1101/2020.04.29.069054v2.full,https://www.cell.com/cell/fulltext/S0092-8674(20)30820-5,,,,,,"Biorxiv: ""COVID-19 longitudinal, antibody waning"""
Kahre et al.,Fei et al.,included,-,,,https://www.nature.com/articles/s41598-021-94453-5,https://www.medrxiv.org/content/10.1101/2021.03.10.21253273v1.full-text,,,,,,
Maine et al.,Fei et al.,excluded,special population (largely hospitalized individuals),,,https://www.sciencedirect.com/science/article/pii/S1386653220304054?via%3Dihub,,,,,,,
Carreño et al.,Google,excluded,"special population (healthcare workers), post-vaccine seroreversion",,,https://www.sciencedirect.com/science/article/pii/S2589004221009056,https://www.medrxiv.org/content/10.1101/2021.02.24.21252340v1.full-text,,,,,,
Thiruvengadam et al.,Google,included,-,,,https://www.ajtmh.org/view/journals/tpmd/105/1/article-p66.xml,https://www.medrxiv.org/content/10.1101/2021.02.04.21251140v1.full-text,,,,,,
Alvim et al.,Google,included,-,,,https://www.medrxiv.org/content/10.1101/2020.07.13.20152884v6.full-text,,,,,,,
McGregor et al.,Google,included,-,,,https://www.medrxiv.org/content/10.1101/2021.10.26.21265501v1.full-text,,,,,,,
Sim et al.,Google,excluded,special population (healthcare workers),,,https://journals.sagepub.com/doi/10.1177/00045632211030957,,,,,,,
Goto et al.,Google,included,-,,,https://www.frontiersin.org/articles/10.3389/fmicb.2021.661187/full,,,,,,,
Choe et al.,Google,included,-,,,https://wwwnc.cdc.gov/eid/article/27/3/20-4543_article,,,,,,,
Rodeles et al.,Google,excluded,no non-serologic initial diagnosis,,,https://iris.paho.org/handle/10665.2/54288,,,,,,,
Domènech-Montoliu et al.,Google,excluded,no non-serologic initial diagnosis,,,https://www.mdpi.com/2673-8112/1/1/6/htm,,,,,,,
Andorra: national,search from representative samples,included,-,,,https://www.sciencedirect.com/science/article/pii/S266677622100096X  [n-43],,,,,,,
Caldari Ortona (Villa Caldari),search from representative samples,included,-,,,https://www.mdpi.com/2076-2607/8/11/1711/htm  [n-107],,,,,,,
California (COVIDVu),search from representative samples,excluded,subset of already included samples,,,https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab379/6329153  [n-1],,,,,,,
Canada (Ab-C): national,search from representative samples,excluded,no non-serologic initial diagnosis,,,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789086  [n-203],,,,,,,
Canada (CCAHS): national (Colwill et al.),search from representative samples,included,-,,,https://www150.statcan.gc.ca/n1/pub/82-003-x/2022004/article/00003-eng.htm  [n-261],https://onlinelibrary.wiley.com/doi/10.1002/cti2.1380  [n-264],,,,,,
Cantabria,search from representative samples,included,-,,,https://www.nature.com/articles/s41598-021-89236-x  [n-46],,,,,,,
Chelyabinsk and Sverdlovsk regions,search from representative samples,excluded,Obolensk ELISA,,,https://www.epidemvac.ru/jour/article/view/1283,,,,,,,
Cogne,search from representative samples,excluded,no non-serologic initial diagnosis,,,https://www.medrxiv.org/content/10.1101/2021.03.19.21253962v1.full  [n-297],,,,,,,
Connecticut,search from representative samples,included,-,,,https://www.amjmed.com/article/S0002-9343(20)30909-8/fulltext  [n-2],,,,,,,
"Coquimbo-La Serena, Greater Santiago, Talca ",search from representative samples,excluded,assays not used individually,,,https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3933650  [n-100],,,,,,,
"Davis, Salt Lake, Summit, and Utah counties",search from representative samples,included,-,,,https://issuu.com/ecclesschool/docs/utah_hero_report_11.24.20_gardner_at_front,,,,,,,
Delhi,search from representative samples,included,-,,,https://academic.oup.com/trstmh/advance-article/doi/10.1093/trstmh/trab109/6335791  [n-83],"https://www.cureus.com/articles/72911-second-wave-of-the-covid-19-pandemic-in-delhi-india-high-seroprevalence-not-a-deterrent  [n-86]  ,  https://www.medrxiv.org/content/10.1101/2021.12.28.21268451v1.full  [n-153]",,,,,,
Denmark (SSI): national + 30 municipalities subset,search from representative samples,included,-,,,"https://link.springer.com/article/10.1007/s10654-021-00796-8  [n-22]  ,  https://files.ssi.dk/praevalensundersoegelse_runde4  [n-194]",https://covid19.ssi.dk/-/media/cdn/files/praevalensundersoegelse_runde5.pdf?la=da  [n-195],,,,,,
Denmark (We test): national,search from representative samples,included,-,,,https://journals.asm.org/doi/10.1128/Spectrum.01330-21  [n-105],,,,,,,
El Omrane + La Goulette,search from representative samples,included,-,,,https://www.researchsquare.com/article/rs-1317280/v2  [n-196],,,,,,,
Ethiopia: 14 towns (including Addis Ababa #2),search from representative samples,included,-,,,https://www.sciencedirect.com/science/article/pii/S1201971221006615  [n-98],,,,,,,
"Finland (Uusimaa), 4 month seroreversion",search from representative samples,included,-,,,https://thl.fi/en/web/thlfi-en/-/study-by-thl-and-welfare-and-the-city-of-helsinki-antibodies-elicited-by-coronavirus-infection-persist-for-at-least-four-months,,,,,,,
"Finland (Uusimaa), 6 month seroreversion",search from representative samples,included,-,,,https://thl.fi/en/web/thlfi-en/-/thl-s-study-majority-of-people-who-have-had-a-coronavirus-infection-retain-antibodies-for-over-six-months,,,,,,,
Florida: Hillsborough County,search from representative samples,included,-,,,https://wwwnc.cdc.gov/eid/article/28/3/21-1495_article,,,,,,,
Gauteng,search from representative samples,included,-,,,https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyab217/6414575?rss=1  [n-99],,,,,,,
Germany (Corona-BUND / Forsa),search from representative samples,excluded,assays not used individually,,,https://www.ifo.de/DocDL/studie-2020-corona-bund-endbericht.pdf,,,,,,,
"Grand Est, Île-de-France, Nouvelle-Aquitaine",search from representative samples,included,-,,,https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyab110/6323645  [n-31],,,,,,,
Great Britain (UK BioBank),search from representative samples,excluded,no non-serologic initial diagnosis,,,https://www.ukbiobank.ac.uk/media/zusjljce/ukb_serologystudy_report_month2_final-1.pdf,https://www.ukbiobank.ac.uk/media/x0nd5sul/ukb_serologystudy_report_revised_6months_jan21.pdf,,,,,,
"Haveri et al. (via Uusimaa, Finland)",search from representative samples,included,-,,,https://onlinelibrary.wiley.com/doi/10.1002/eji.202149535,,,,,,,
Holyoke,search from representative samples,included,-,,,https://www.medrxiv.org/content/10.1101/2021.10.13.21264975v1  [n-78],,,,,,,
Houston,search from representative samples,excluded,assays not used individually,,,https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiab203/6258999,,,,,,,
Hyderabad,search from representative samples,included,-,,,https://www.sciencedirect.com/science/article/pii/S2772707621000229  [n-101],,,,,,,
Iceland: national,search from representative samples,included,-,,,https://www.nejm.org/doi/full/10.1056/NEJMoa2026116,,,,,,,
India: national,search from representative samples,included,-,,,"https://www.ijidonline.com/article/S1201-9712(21)00442-2/fulltext  ,  https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30544-1/fulltext  [n-85]  ,  https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003877  [n-97]",,,,,,,
Ireland: national,search from representative samples,included,-,,,"https://academic.oup.com/jid/article/224/6/1100/6311910  ,  https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.48.2001741  [n-111]",,,,,,,
Irkutsk region,search from representative samples,excluded,Obolensk ELISA,,,https://journal.microbe.ru/jour/article/view/1370/1149,,,,,,,
Ischgl,search from representative samples,included,-,,,"https://www.medrxiv.org/content/10.1101/2021.02.19.21252089v1.full-text  ,  https://www.nature.com/articles/s43856-021-00007-1  [n-109]",,,,,,,
Jersey,search from representative samples,excluded,no non-serologic initial diagnosis,,,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200609%20SJ.pdf,https://www.gov.je/SiteCollectionDocuments/Government%20and%20administration/R%20Prevalence%20of%20antibodies%2020200707%20SJ.pdf,,,,,,
Kaliningrad region,search from representative samples,excluded,Obolensk ELISA,,,https://journal.niidi.ru/jofin/article/view/1145,,,,,,,
Kashmir (whole region),search from representative samples,included,-,,,https://bmjopen.bmj.com/content/11/9/e053791  [n-91],,,,,,,
Kashmir: Srinagar district,search from representative samples,included,-,,,https://www.ijcmph.com/index.php/ijcmph/article/view/7827  [n-92],,,,,,,
Kennedy et al. (via Arkansas statewide study),search from representative samples,included,-,,,https://academic.oup.com/ofid/article/9/5/ofac154/6553257,,,,,,,
Khabarovsk Krai region,search from representative samples,excluded,Obolensk ELISA,,,https://microbiol.elpub.ru/jour/article/view/983?locale=ru_RU#tab1,,,,,,,
Krasnoyarsk region,search from representative samples,excluded,Obolensk ELISA,,,https://www.actabiomedica.ru/jour/article/view/2872/2184,,,,,,,
Kupferzell,search from representative samples,included,-,,,https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.47.2001752  [n-110],,,,,,,
Lebanon: national,search from representative samples,included,-,,,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07031-z  [n-150],,,,,,,
"Leningrad region, excluding St. Petersburg",search from representative samples,excluded,Obolensk ELISA,,,https://journal.microbe.ru/jour/article/view/1371/1150,,,,,,,
Lima Metropolitana (provinces of Lima + Callao),search from representative samples,included,-,,,https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00081-X/fulltext  [k-15],,,,,,,
Lithuania: 6 cities and municipalities,search from representative samples,included,-,,,"n-172  ,  https://www.journals.vu.lt/AML/article/view/22344",,,,,,,
Los Angeles County,search from representative samples,included,-,,,https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788249  [n-174],,,,,,,
greater Male’ area,search from representative samples,included,-,,,https://apjai-journal.org/wp-content/uploads/2022/01/AP-040721-1177.pdf  [n-151],,,,,,,
Mitte (in Berlin) and Bad Feilnbach,search from representative samples,included,-,,,https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Berlin-Mitte.html  [n-236],https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Dokumente/Abschlussbericht_2021.pdf?__blob=publicationFile  [n-295],,,,,,
"Miyagi, Osaka, Tokyo, Aichi, Fukuoka",search from representative samples,included,-,,,https://www.mhlw.go.jp/content/10900000/000934787.pdf  [n-280],,,,,,,
Moscow,search from representative samples,excluded,Obolensk ELISA,,,https://www.phdynasty.ru/en/catalog/magazines/infectious-diseases/2020/volume-18-issue-4/40419,,,,,,,
Munich,search from representative samples,excluded,no non-serologic initial diagnosis,,,https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06589-4,,,,,,,
Murmansk region,search from representative samples,excluded,Obolensk ELISA,,,https://hiv.bmoc-spb.ru/jour/article/view/605#,,,,,,,
Netherlands: Hartog et al.,search from representative samples,excluded,no non-serologic initial diagnosis,,,https://academic.oup.com/cid/article/73/12/2155/6149064#supplementary-data,,,,,,,
Novosibirsk region,search from representative samples,excluded,Obolensk ELISA,,,https://virusjour.elpub.ru/jour/article/view/539,,,,,,,
"Odisha: Bhubaneswar, Berhampur, Rourkela",search from representative samples,included,-,,,"https://www.cambridge.org/core/journals/epidemiology-and-infection/article/seroprevalence-of-sarscov2-in-bhubaneswar-india-findings-from-three-rounds-of-community-surveys/29A7905F297A1EFA68749AC3C6383300  [n-94]  ,  https://www.nature.com/articles/s41598-021-89877-y  [n-93]",,,,,,,
Portugal (Castro et al.),search from representative samples,included,-,,,"https://onlinelibrary.wiley.com/doi/full/10.1002/eji.202149619  ,  https://wwwnc.cdc.gov/eid/article/27/11/21-0636_article",,,,,,,
Puducherry: Puducherry district,search from representative samples,included,-,,,https://wwwnc.cdc.gov/eid/article/27/2/20-4480_article  [n-87],,,,,,,
Puerto Madryn,search from representative samples,included,-,,,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263679  [n-248],,,,,,,
Saarland,search from representative samples,included,-,,,https://www.nature.com/articles/s43856-022-00100-z  [n-289],,,,,,,
St. Petersburg (from Rospotrebnadzor),search from representative samples,excluded,Obolensk ELISA,,,https://journal.microbe.ru/jour/article/view/1372/1151#,,,,,,,
Saratov region,search from representative samples,excluded,Obolensk ELISA,,,https://journal.microbe.ru/jour/article/view/1413?locale=en_US,,,,,,,
Scheiblauer et al. (via Saarland study),search from representative samples,included,-  (Mikrogen GmbH recomLine excluded due to threshold for avidity artiifically deflating sensitivity estimate),,,https://www.sciencedirect.com/science/article/pii/S138665322100319X  [n-290],,,,,,,
Silveira et al. (via Rio Grande do Sul [9 cities] location),search from representative samples,included,-,,,https://www.scielo.br/j/bjid/a/9X43shvTQCxvmMhkNFwFRrq/?lang=en,,,,,,,
Spain: national,search from representative samples,included,-,,,"https://portalcne.isciii.es/enecovid19/informes/informe_final.pdf  [n-104]  ,  https://www.mscbs.gob.es/gabinetePrensa/notaPrensa/pdf/15.12151220163348113.pdf  [n-45]","https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31483-5/fulltext  [n-44]  ,  ",,,,,,
Stavropol Krai,search from representative samples,excluded,Obolensk ELISA,,,https://journal.niidi.ru/jofin/article/view/1273,,,,,,,
Straubing,search from representative samples,included,-,,,https://www.rki.de/DE/Content/Gesundheitsmonitoring/Studien/cml-studie/Factsheet_Straubing.html  [n-234],,,,,,,
Switzerland: 11 cantons (for Corona Immunitas),search from representative samples,included,-,,,https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-022-02431-z  [n-299],,,,,,,
Tamil Nadu: Chennai,search from representative samples,included,-,,,"https://wwwnc.cdc.gov/eid/article/27/2/20-3938_article  [n-88]  ,  https://academic.oup.com/trstmh/article/115/11/1350/6370308  [n-89]",,,,,,,
Tanjung Priok sub-district,search from representative samples,included,-,,,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0261931  [n-152],,,,,,,
Tatarstan,search from representative samples,excluded,Obolensk ELISA,,,https://microbiol.elpub.ru/jour/article/view/940?locale=en_US,,,,,,,
"Ticino (by cantonal office, not for Corona Immunitas)",search from representative samples,excluded,no non-serologic initial diagnosis,,,https://smw.ch/article/doi/smw.2021.w30116,,,,,,,
Tirschenreuth district,search from representative samples,excluded,assays not used individually,,,https://www.mdpi.com/1999-4915/13/6/1118/htm  [n-29],,,,,,,
Trento (5 municipalities),search from representative samples,excluded,no non-serologic initial diagnosis,,,https://www.medrxiv.org/content/10.1101/2020.11.11.20229062v2.full,,,,,,,
Tyumen region,search from representative samples,excluded,Obolensk ELISA,,,https://microbiol.elpub.ru/jour/article/view/890?locale=en_US#,,,,,,,
USA (COVIDVu): national,search from representative samples,included,-,,,"n-143  ,  https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab626/6318822",,,,,,,
Vaud (for Corona Immunitas),search from representative samples,included,-,,,https://academic.oup.com/ofid/article/8/7/ofab149/6189274  [n-301],,,,,,,
Vo',search from representative samples,included,-,,,https://www.nature.com/articles/s41467-021-24622-7#Sec26,,,,,,,
Weißenkirchen/Wachau,search from representative samples,excluded,no non-serologic initial diagnosis,,,https://www.frontiersin.org/articles/10.3389/fmed.2021.653630/full,,,,,,,
West Bengal: Paschim Medinipur,search from representative samples,included,-,,,https://www.medrxiv.org/content/10.1101/2020.09.12.20193219v1.full  [n-95],,,,,,,
Wisconsin,search from representative samples,excluded,no non-serologic initial diagnosis,,,https://www.medrxiv.org/content/10.1101/2020.12.18.20248479v2.full,,,,,,,
Wuhan #2,search from representative samples,excluded,assays not used individually,,,https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00238-5/fulltext,,,,,,,